Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below

Sequenced Treatment Alternatives to Relieve Depression (STAR*D). Part 2: Study outcomes.

Author information

  • University of Pittsburgh School of Medicine, Western Pychiatric Institute and Clinic, Pittsburgh, Pennsylvania 15213, USA. HowlandRH@upmc.edu

Abstract

This article reviews the main outcome findings from the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study. The study compared the efficacy and tolerability of a range of antidepressant therapies through four sequential levels of treatment with the goal of achieving remission. Remission rates based on the primary outcome measure (Hamilton Rating Scale for Depression) were 28% (Level 1 citalopram), 17% to 30% (Level 2 treatments), 12% to 25% (Level 3 treatments), and 7% to 14% (Level 4 treatments). For patients not responding adequately to an initial trial of citalopram, subsequent treatment strategies may be effective. When more treatment steps are required, however, lower acute remission rates, greater degrees of treatment intolerance, and higher relapse rates during follow up are seen. There were few differences among treatments within each level related to efficacy or tolerability, although patients had clear preferences for or against certain treatments.

PMID:
18935932
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Write to the Help Desk